Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
MISSISSAUGA, ON, Nov. 3, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it plans to commence a Phase 3 clinical study of Pennsaid 2% for the treatment of acute pain to support regulatory approval applications for Pennsaid 2% in international